Cargando…
Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
CAR-T cells present a highly effective therapeutic option for several malignant diseases, based on their ability to recognize the selected tumor surface marker in an MHC-independent manner. This triggers cell activation and cytokine production, resulting in the killing of the cancerous cell presenti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200817/ https://www.ncbi.nlm.nih.gov/pubmed/37223115 http://dx.doi.org/10.1016/j.omto.2023.04.005 |
_version_ | 1785045134470021120 |
---|---|
author | Lainšček, Duško Golob-Urbanc, Anja Mikolič, Veronika Pantović-Žalig, Jelica Malenšek, Špela Jerala, Roman |
author_facet | Lainšček, Duško Golob-Urbanc, Anja Mikolič, Veronika Pantović-Žalig, Jelica Malenšek, Špela Jerala, Roman |
author_sort | Lainšček, Duško |
collection | PubMed |
description | CAR-T cells present a highly effective therapeutic option for several malignant diseases, based on their ability to recognize the selected tumor surface marker in an MHC-independent manner. This triggers cell activation and cytokine production, resulting in the killing of the cancerous cell presenting markers recognized by the chimeric antigen receptor. CAR-T cells are highly potent serial killers that may cause serious side effects, so their activity needs to be carefully controlled. Here we designed a system to control the proliferation and activation state of CARs based on downstream NFAT transcription factors, whose activity can be regulated via chemically induced heterodimerization systems. Chemical regulators were used to either transiently trigger engineered T cell proliferation or suppress CAR-mediated activation when desired or to enhance activation of CAR-T cells upon engagement of cancer cells, shown also in vivo. Additionally, an efficient sensor to monitor activated CD19 CAR-T cells in vivo was introduced. This implementation in CAR-T cell regulation offers an efficient way for on-demand external control of CAR-T cell activity to improve their safety. |
format | Online Article Text |
id | pubmed-10200817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-102008172023-05-23 Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor Lainšček, Duško Golob-Urbanc, Anja Mikolič, Veronika Pantović-Žalig, Jelica Malenšek, Špela Jerala, Roman Mol Ther Oncolytics Original Article CAR-T cells present a highly effective therapeutic option for several malignant diseases, based on their ability to recognize the selected tumor surface marker in an MHC-independent manner. This triggers cell activation and cytokine production, resulting in the killing of the cancerous cell presenting markers recognized by the chimeric antigen receptor. CAR-T cells are highly potent serial killers that may cause serious side effects, so their activity needs to be carefully controlled. Here we designed a system to control the proliferation and activation state of CARs based on downstream NFAT transcription factors, whose activity can be regulated via chemically induced heterodimerization systems. Chemical regulators were used to either transiently trigger engineered T cell proliferation or suppress CAR-mediated activation when desired or to enhance activation of CAR-T cells upon engagement of cancer cells, shown also in vivo. Additionally, an efficient sensor to monitor activated CD19 CAR-T cells in vivo was introduced. This implementation in CAR-T cell regulation offers an efficient way for on-demand external control of CAR-T cell activity to improve their safety. American Society of Gene & Cell Therapy 2023-04-26 /pmc/articles/PMC10200817/ /pubmed/37223115 http://dx.doi.org/10.1016/j.omto.2023.04.005 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Lainšček, Duško Golob-Urbanc, Anja Mikolič, Veronika Pantović-Žalig, Jelica Malenšek, Špela Jerala, Roman Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor |
title | Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor |
title_full | Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor |
title_fullStr | Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor |
title_full_unstemmed | Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor |
title_short | Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor |
title_sort | regulation of cd19 car-t cell activation based on an engineered downstream transcription factor |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200817/ https://www.ncbi.nlm.nih.gov/pubmed/37223115 http://dx.doi.org/10.1016/j.omto.2023.04.005 |
work_keys_str_mv | AT lainscekdusko regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor AT goloburbancanja regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor AT mikolicveronika regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor AT pantoviczaligjelica regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor AT malensekspela regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor AT jeralaroman regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor |